Experiment: 7D11

SOLUTION NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
1	2D 1H-15N HSQC	1.8 mM [U-95% 15N] WRKY1-N, 5 % v/v [U-99% 2H] D2O, 95 % v/v H2O, 25 mM HEPES, 100 mM sodium chloride, 20 uM ZnCl2, 10 mM DTT, 2 % v/v protease inhibitor, 0.2 % v/v sodium azide	95% H2O/5% D2O	125 mM	7.0	1 atm	298	Bruker AVANCE 500
2	2D 1H-15N HSQC	1.8 mM [U-95% 15N] WRKY1-N, 5 % v/v [U-99% 2H] D2O, 95 % v/v H2O, 25 mM HEPES, 100 mM sodium chloride, 20 uM ZnCl2, 10 mM DTT, 2 % v/v protease inhibitor, 0.2 % v/v sodium azide	95% H2O/5% D2O	125 mM	7.0	1 atm	298	Bruker AVANCE 900
3	2D 1H-13C HSQC	1.8 mM [U-95% 13C; U-95% 15N] WRKY1-N, 5 % v/v [U-99% 2H] D2O, 95 % v/v H2O, 25 mM HEPES, 100 mM sodium chloride, 20 uM ZnCl2, 10 mM DTT, 5 % v/v DSS, 2 % v/v protease inhibitor, 0.2 % v/v sodium azide	95% H2O/5% D2O	125 mM	7.0	1 atm	298	Bruker AVANCE 500
4	2D 1H-13C HSQC	1.8 mM [U-95% 13C; U-95% 15N] WRKY1-N, 5 % v/v [U-99% 2H] D2O, 95 % v/v H2O, 25 mM HEPES, 100 mM sodium chloride, 20 uM ZnCl2, 10 mM DTT, 5 % v/v DSS, 2 % v/v protease inhibitor, 0.2 % v/v sodium azide	95% H2O/5% D2O	125 mM	7.0	1 atm	298	Bruker AVANCE 900
5	2D 1H-13C HSQC aromatic	1.8 mM [U-95% 13C; U-95% 15N] WRKY1-N, 5 % v/v [U-99% 2H] D2O, 95 % v/v H2O, 25 mM HEPES, 100 mM sodium chloride, 20 uM ZnCl2, 10 mM DTT, 5 % v/v DSS, 2 % v/v protease inhibitor, 0.2 % v/v sodium azide	95% H2O/5% D2O	125 mM	7.0	1 atm	298	Bruker AVANCE 900
6	3D HNCA	1.8 mM [U-95% 13C; U-95% 15N] WRKY1-N, 5 % v/v [U-99% 2H] D2O, 95 % v/v H2O, 25 mM HEPES, 100 mM sodium chloride, 20 uM ZnCl2, 10 mM DTT, 5 % v/v DSS, 2 % v/v protease inhibitor, 0.2 % v/v sodium azide	95% H2O/5% D2O	125 mM	7.0	1 atm	298	Bruker AVANCE 500
7	3D HN(CO)CA	1.8 mM [U-95% 13C; U-95% 15N] WRKY1-N, 5 % v/v [U-99% 2H] D2O, 95 % v/v H2O, 25 mM HEPES, 100 mM sodium chloride, 20 uM ZnCl2, 10 mM DTT, 5 % v/v DSS, 2 % v/v protease inhibitor, 0.2 % v/v sodium azide	95% H2O/5% D2O	125 mM	7.0	1 atm	298	Bruker AVANCE 500
8	3D HNCACB	1.8 mM [U-95% 13C; U-95% 15N] WRKY1-N, 5 % v/v [U-99% 2H] D2O, 95 % v/v H2O, 25 mM HEPES, 100 mM sodium chloride, 20 uM ZnCl2, 10 mM DTT, 5 % v/v DSS, 2 % v/v protease inhibitor, 0.2 % v/v sodium azide	95% H2O/5% D2O	125 mM	7.0	1 atm	298	Bruker AVANCE 500
9	3D CBCA(CO)NH	1.8 mM [U-95% 13C; U-95% 15N] WRKY1-N, 5 % v/v [U-99% 2H] D2O, 95 % v/v H2O, 25 mM HEPES, 100 mM sodium chloride, 20 uM ZnCl2, 10 mM DTT, 5 % v/v DSS, 2 % v/v protease inhibitor, 0.2 % v/v sodium azide	95% H2O/5% D2O	125 mM	7.0	1 atm	298	Bruker AVANCE 500
10	3D HBHA(CO)NH	1.8 mM [U-95% 13C; U-95% 15N] WRKY1-N, 5 % v/v [U-99% 2H] D2O, 95 % v/v H2O, 25 mM HEPES, 100 mM sodium chloride, 20 uM ZnCl2, 10 mM DTT, 5 % v/v DSS, 2 % v/v protease inhibitor, 0.2 % v/v sodium azide	95% H2O/5% D2O	125 mM	7.0	1 atm	298	Bruker AVANCE 500
11	3D HNCO	1.8 mM [U-95% 13C; U-95% 15N] WRKY1-N, 5 % v/v [U-99% 2H] D2O, 95 % v/v H2O, 25 mM HEPES, 100 mM sodium chloride, 20 uM ZnCl2, 10 mM DTT, 5 % v/v DSS, 2 % v/v protease inhibitor, 0.2 % v/v sodium azide	95% H2O/5% D2O	125 mM	7.0	1 atm	298	Bruker AVANCE 500
12	3D C(CO)NH	1.8 mM [U-95% 13C; U-95% 15N] WRKY1-N, 5 % v/v [U-99% 2H] D2O, 95 % v/v H2O, 25 mM HEPES, 100 mM sodium chloride, 20 uM ZnCl2, 10 mM DTT, 5 % v/v DSS, 2 % v/v protease inhibitor, 0.2 % v/v sodium azide	95% H2O/5% D2O	125 mM	7.0	1 atm	298	Bruker AVANCE 500
13	3D H(CCO)NH	1.8 mM [U-95% 13C; U-95% 15N] WRKY1-N, 5 % v/v [U-99% 2H] D2O, 95 % v/v H2O, 25 mM HEPES, 100 mM sodium chloride, 20 uM ZnCl2, 10 mM DTT, 5 % v/v DSS, 2 % v/v protease inhibitor, 0.2 % v/v sodium azide	95% H2O/5% D2O	125 mM	7.0	1 atm	298	Bruker AVANCE 500
14	3D HCCH-COSY	1.8 mM [U-95% 13C; U-95% 15N] WRKY1-N, 5 % v/v [U-99% 2H] D2O, 95 % v/v H2O, 25 mM HEPES, 100 mM sodium chloride, 20 uM ZnCl2, 10 mM DTT, 5 % v/v DSS, 2 % v/v protease inhibitor, 0.2 % v/v sodium azide	95% H2O/5% D2O	125 mM	7.0	1 atm	298	Bruker AVANCE 500
15	3D CCH-TOCSY	1.8 mM [U-95% 13C; U-95% 15N] WRKY1-N, 5 % v/v [U-99% 2H] D2O, 95 % v/v H2O, 25 mM HEPES, 100 mM sodium chloride, 20 uM ZnCl2, 10 mM DTT, 5 % v/v DSS, 2 % v/v protease inhibitor, 0.2 % v/v sodium azide	95% H2O/5% D2O	125 mM	7.0	1 atm	298	Bruker AVANCE 500
16	3D 1H-15N NOESY	1.8 mM [U-95% 15N] WRKY1-N, 5 % v/v [U-99% 2H] D2O, 95 % v/v H2O, 25 mM HEPES, 100 mM sodium chloride, 20 uM ZnCl2, 10 mM DTT, 2 % v/v protease inhibitor, 0.2 % v/v sodium azide	95% H2O/5% D2O	125 mM	7.0	1 atm	298	Bruker AVANCE 900
17	3D 1H-13C NOESY aliphatic	1.8 mM [U-95% 13C; U-95% 15N] WRKY1-N, 5 % v/v [U-99% 2H] D2O, 95 % v/v H2O, 25 mM HEPES, 100 mM sodium chloride, 20 uM ZnCl2, 10 mM DTT, 5 % v/v DSS, 2 % v/v protease inhibitor, 0.2 % v/v sodium azide	95% H2O/5% D2O	125 mM	7.0	1 atm	298	Bruker AVANCE 900
18	3D 1H-13C NOESY aromatic	1.8 mM [U-95% 13C; U-95% 15N] WRKY1-N, 5 % v/v [U-99% 2H] D2O, 95 % v/v H2O, 25 mM HEPES, 100 mM sodium chloride, 20 uM ZnCl2, 10 mM DTT, 5 % v/v DSS, 2 % v/v protease inhibitor, 0.2 % v/v sodium azide	95% H2O/5% D2O	125 mM	7.0	1 atm	298	Bruker AVANCE 900

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Bruker	AVANCE	500
2	Bruker	AVANCE	900

NMR Refinement
Method	Details	Software
simulated annealing		X-PLOR NIH

NMR Ensemble Information
Conformer Selection Criteria	structures with the lowest energy
Conformers Calculated Total Number	100
Conformers Submitted Total Number	20
Representative Model	1 (closest to the average)

Computation: NMR Software
#	Classification	Version	Software Name	Author
1	refinement	X-PLOR NIH		Schwieters, Kuszewski, Tjandra and Clore
2	structure calculation	DYANA		Guntert, Braun and Wuthrich
6	structure calculation	SANE		Duggan, Legge, Dyson & Wright
7	structure calculation	CANDID		Herrmann, Guntert and Wuthrich
3	chemical shift assignment	NMRView		Johnson, One Moon Scientific
4	peak picking	NMRView		Johnson, One Moon Scientific
8	processing	NMRPipe		Delaglio, Grzesiek, Vuister, Zhu, Pfeifer and Bax

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.